Department of Cardiology, CHU, Nancy, France.
Department of Cardiovascular Surgery, CHU, Nancy, France.
Catheter Cardiovasc Interv. 2020 Nov;96(5):E542-E551. doi: 10.1002/ccd.28813. Epub 2020 Feb 26.
OBJECTIVE: The aim of our study was to evaluate the outcome of patients with severe aortic stenosis presenting with acute decompensated heart failure (ADHF) and planned for transcatheter aortic valve implantation (TAVI) and to study the variables influencing their prognosis. METHODS: Our retrospective study included 801 patients planned for TAVI in our center. Seven hundred and fifty-six underwent TAVI and were categorized according to ADHF as the initial clinical presentation into two groups: ADHF group (n = 261) and no-ADHF group (n = 495). Pre as well as periprocedural outcomes and 1 year mortality were analyzed. RESULTS: Among the patients planned for the TAVI procedure, 45 patients remained untreated: 35 patients died while waiting to undergo TAVI which represented 20% of all deaths in our study, ADHF was observed in 23 of 45 (51%) these untreated patients. The 1-year all-cause mortality rate was significantly higher in the ADHF group versus the no-ADHF group (27% vs. 15%, p < .0001). In multivariate analysis, male gender (odds ratio [OR] =2.5, 95% confidence interval [CI]: 1.37-4.57, p = .03), body mass index <25 kg/m (OR = 2.76, 95% CI: 1.51-5.04, p = .0009), and logistic EuroSCORE II ≥20% (OR = 3.04, 95% CI: 1.56-5.94, p = .001) were associated with a higher 1-year mortality in the ADHF group. CONCLUSION: The patients eligible for TAVI presenting with ADHF were associated with a higher mortality for both: while on the waiting list for TAVI as well as at 1-year follow-up and thus asking for clearer criteria to prioritize action in this high-risk TAVI patients.
目的:本研究旨在评估因急性失代偿性心力衰竭(ADHF)而计划行经导管主动脉瓣植入术(TAVI)的重度主动脉瓣狭窄患者的结局,并研究影响其预后的变量。
方法:我们的回顾性研究纳入了计划在我院接受 TAVI 的 801 例患者。756 例患者接受了 TAVI,并根据 ADHF 作为初始临床表现分为两组:ADHF 组(n=261)和非 ADHF 组(n=495)。分析了术前、围手术期结局和 1 年死亡率。
结果:在计划接受 TAVI 手术的患者中,有 45 例未接受治疗:35 例在等待 TAVI 期间死亡,占本研究所有死亡人数的 20%,在这 45 例未接受治疗的患者中,有 23 例(51%)出现 ADHF。ADHF 组的 1 年全因死亡率明显高于非 ADHF 组(27% vs. 15%,p<0.0001)。多变量分析显示,男性(优势比[OR] =2.5,95%置信区间[CI]:1.37-4.57,p=0.03)、体重指数<25kg/m(OR=2.76,95%CI:1.51-5.04,p=0.0009)和逻辑 EuroSCORE II ≥20%(OR=3.04,95%CI:1.56-5.94,p=0.001)与 ADHF 组 1 年死亡率升高相关。
结论:因 ADHF 而适合接受 TAVI 的患者,在 TAVI 等待名单上以及在 1 年随访期间,死亡率均较高,因此需要更明确的标准来为这些高危 TAVI 患者确定治疗优先级。
Catheter Cardiovasc Interv. 2020-11
Arch Cardiovasc Dis. 2017-4-12
Struct Heart. 2024-10-28
Heart Fail Rev. 2023-9
Eur Heart J Qual Care Clin Outcomes. 2023-11-2